OakChart

LB Pharmaceuticals Inc

LBRXHealthcare·Biotechnology·USA·Small·NASD·Nov 12 • 3:59 PM ET

42.46-2.25 (-5.03%)
2026-11-13 14:01 CET
Market cap
$1.37B
Revenue, TTM
0.00 USD m
Net income, TTM
-141.19 USD m
Free cash flow, TTM
-143.82 USD m
EPS diluted, TTM
-4.63
Price / earnings
-
Compare

Price

LBRX against its 20, 50 and 200-day averages
Terms2050200BeatMiss
Patternshover a marker to name it
RS 77Sales 0.00Price0.0030.0040.0050.00707K1.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LBRXclose 42.4620-day 40.5150-day 40.28200-day 33.4742.4652w high 50.1652-week range, not 6 months

15.4% under the 52-week high of 50.16 on 25 Aug 2026. 52-week low 14.40 on 14 Nov 2025. Last 15 sessions, 20.5% high to low

Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average

Setup. RS line 77
CANSLIM 3 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High
VCP 4 of 6 — fails: 52-Week High/Low: 0-10% below High; Average True Range: Under 2
Minervini 3 of 4 — fails: 52-Week High/Low: 0-10% below High
Zanger 3 of 5 — fails: 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5
Leaders 3 of 5 — fails: Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 3 of 4 — fails: Average Volume: Over 500K
Accumulation 3 of 4 — fails: Institutional Transactions: Over +10%
Relative Strength 2 of 3 — fails: Average Volume: Over 500K

Profile

LBRX
52-week range, 78% of the way up
14.4050.16

LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.

IndexRUT
Employees27
IPOSep 11, 2025
Beta0.82
ATR, 14d2.55
Rel volume0.00
Short float25.83%
Insider own25.84%
Inst own87.73%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap$1.37B
Enterprise Value975.53M
Income-141.19M
Sales0.00M
Book / share12.94
Cash / share12.48
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees27
IPOSep 11, 2025

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book3.28
Price / cash3.40
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio14.78
Current Ratio14.78
Debt / equity0.01
Long-term debt / equity0.01
Options and shortYes / Yes

Earnings

Earnings / share-4.63
Earnings next year-5.74
Earnings next quarter-1.85
Earnings this year-94.06%
Earnings next year5.56%
Earnings growth, 5 years-26.57%
Past earnings growth-15.94% -
Past sales growth- -
Earnings vs last year-483.12%
Sales vs last year-
Earnings vs last quarter-1169.91%
Sales vs last quarter-
EarningsNov 05 AMC
Surprise-10.44% -

Ownership

Insiders own25.84%
Insider trades0.00%
Institutions own87.73%
Institution trades7.64%
Return on assets-36.48%
Return on equity-38.80%
Return on capital-33.47%
Gross Margin-
Operating margin-
Profit Margin-
20-day average4.82%
50-day average5.41%
200-day average26.86%

Technical

Shares out32.27M
Shares floating24.00M
Short / float25.83%
Short ratio17.08
Short interest6.20M
52-week high50.16 -15.4%
52-week low14.40 +194.9%
Volatility7.04% 6.64%
Average range2.55
Strength index55.57
Market sensitivity0.82
Relative volume0.00
Avg Volume362.98K
Volume0

Performance

Perf Week11.47%
Perf Month24.88%
Perf Quarter-11.13%
Perf Half Y35.18%
Perf YTD90.75%
Perf Year181.56%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recommendation1.17
Target Price58.92
Prev Close42.46
Price42.46
Change %0.00%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
Oct 09, 2026InitiatedCanaccord GenuityBuy$65+53.1%
Oct 06, 2026InitiatedGuggenheimBuy$80+88.4%
Oct 05, 2026DowngradeRoth CapitalBuy → Neutral$35-17.6%
Oct 02, 2026InitiatedNeedhamBuy$68+60.2%
Jul 21, 2026InitiatedBMO Capital MarketsOutperform$46+8.3%
Jul 07, 2026InitiatedWolfe ResearchOutperform$45+6.0%
Apr 27, 2026InitiatedH.C. WainwrightBuy$45+6.0%
Apr 10, 2026InitiatedCraig HallumBuy$36-15.2%
Jan 09, 2026InitiatedRoth CapitalBuy
Oct 06, 2025InitiatedStifelBuy$27-36.4%

Peers

Mkt cap
TickerCompanyMkt cap
MPLTMapLight Therapeutics Inc392.92M
ANROAlto Neuroscience Inc1.23B
ACADAcadia Pharmaceuticals Inc3.13B
NMRANeumora Therapeutics Inc84.18M
AXSMAxsome Therapeutics Inc7.59B
VNDAVanda Pharmaceuticals Inc241.88M
SPTXSeaport Therapeutics Inc1.08B
HELPHelus Pharma Inc661.16M
RLMDRelmada Therapeutics Inc459.75M
MNOVMedicinova Inc68.91M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
PRENSKY ZACHARYFormer OfficerJun 09 '26Proposed Sale29.4916,500486,566Jun 09 05:41 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
IWMiShares Russell 2000 Index FundAUM: 77.86B
VXFVanguard Extended Market Index ETFAUM: 30.79B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 530.07M
SCHASchwab U.S. Small-Cap ETFAUM: 22.44B
VTWOVanguard Russell 2000 Index ETFAUM: 16.90B
IWNiShares Russell 2000 Value ETFAUM: 14.17B
IWOiShares Russell 2000 Growth ETFAUM: 14.25B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.73B
IWCiShares Micro-Cap ETFAUM: 1.23B

News

latest 14 of 98

Quarterly earnings

2026Q3 EPS -1.790 missed -1.621, from -0.610 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
EPS
0.0000-1.7902025Q2 EPS -1.44025Q22025Q3 EPS -0.610 against -0.57025Q32025Q4 EPS -0.450 against -0.44825Q42026Q1 EPS -0.670 against -0.74526Q12026Q2 EPS -1.710 against -0.80426Q22026Q3 EPS -1.790 against -1.62126Q3
Sales, USD millions
0.890-0.892025Q2 sales 0.0025Q22025Q3 sales 0.00 against 0.0025Q32025Q4 sales 0.00 against 0.0025Q42026Q1 sales 0.00 against 0.0026Q12026Q2 sales 0.00 against 0.0026Q22026Q3 sales 0.00 against 0.0026Q3

The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.

PeriodReportedEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mSurpriseYear-ago quarterAnalystsNext session
2026Q3ended 2026-09-302026-11-05 16:30-1.790-1.621-1.7900.000.00EPS +10.4% · sales -vs 2025Q3, year-ago quarter · EPS +193.4% · sales -12 EPS · 8 salesOpen +1.16% vs SPY +0.25%. Close +10.29% vs SPY +0.31%
2026Q2ended 2026-06-302026-08-11 08:30-1.710-0.804-1.7120.000.00EPS +112.8% · sales -vs 2025Q2, year-ago quarter · EPS +18.8% · sales -9 EPS · 6 salesOpen +0.17% vs SPY +0.19%. Close -1.13% vs SPY -0.32%
2026Q1ended 2026-03-312026-05-12 16:30-0.670-0.745-0.6750.000.00EPS -10.1% · sales --6 EPS · 5 salesOpen -1.12% vs SPY +0.04%. Close +3.79% vs SPY +0.56%
2025Q4ended 2025-12-312026-03-26 16:30-0.450-0.448-0.4530.000.00EPS +0.6% · sales --4 EPS · 3 salesOpen +1.67% vs SPY -0.40%. Close -2.81% vs SPY -1.71%
2025Q3ended 2025-09-302025-11-06 08:30-0.610-0.570-0.1410.000.00EPS +7.0% · sales --3 EPS · 2 salesOpen -0.68% vs SPY -0.16%. Close -4.26% vs SPY -1.07%
2025Q2ended 2025-06-302025-09-03 12:00-1.440--0.2170.00-EPS - · sales ----
2026Q4ended 2026-12-31---1.855--0.00EPS - · sales -vs 2025Q4, year-ago quarter · EPS - · sales -12 EPS · 8 sales-
2027Q1ended 2027-03-31---1.813--0.00EPS - · sales -vs 2026Q1, year-ago quarter · EPS - · sales -7 EPS · 6 sales-
2027Q2ended 2027-06-30---1.633--0.00EPS - · sales -vs 2026Q2, year-ago quarter · EPS - · sales -7 EPS · 6 sales-
2027Q3ended 2027-09-30---1.530--0.00EPS - · sales -vs 2026Q3, year-ago quarter · EPS - · sales -7 EPS · 6 sales-
2027Q4ended 2027-12-31---1.476--0.00EPS - · sales -vs 2026Q4, year-ago quarter · EPS - · sales -7 EPS · 6 sales-

Annual earnings

2025FY EPS -3.130 beat -4.028. Sales 0.00 matched 0.00

earnings feed, not the snapshot. Not the statement ratio.

PeriodEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mP/E, earnings feed
2030FYestimate--3.928--220.35-
2029FYestimate--6.075--70.57-
2028FYestimate--6.347--4.90-
2027FYestimate--5.737--0.00-
2026FYestimate--6.074--0.00-
2025FY-3.130-4.028-2.5500.000.00-

Quarterly results

2026Q3 revenue 0.00, from 0.00 a year earlier
Revenue, USD millions
0.890-0.892024Q4 revenue 0.0024Q42025Q1 revenue 0.0025Q12025Q2 revenue 0.0025Q22025Q3 revenue 0.0025Q32025Q4 revenue 0.0025Q42026Q1 revenue 0.0026Q12026Q2 revenue 0.0026Q22026Q3 revenue 0.0026Q3

From the quarterly statement. Not an estimate.

Estimate revisions

Latest snapshot of each period and type. 2026FY E -6.07 per share.
PeriodTypeScaleDateMeanvs prior date
2026FYEper share2026-11-06-6.07+7.5%
2026Q4Eper share2026-11-06-1.86+12.1%
2026FYRper share2026-11-06-6.19+5.5%
2026Q4Rper share2026-11-06-1.87+8.3%
2026Q4Sper share2026-11-060.00-
2026Q3Eper share2026-11-04-1.620.0%
2026Q3Rper share2026-10-26-1.470.0%
2026FYSper share2026-10-140.00-
2026Q3Sper share2026-10-140.00-
2026Q2Eper share2026-08-05-0.800.0%
2026Q2Rper share2026-07-27-0.810.0%
2026Q2Sper share2026-07-060.00-
2026Q1Eper share2026-04-24-0.75-2.5%
2026Q1Sper share2026-04-240.00-
2026Q1Rper share2026-03-27-0.84+44.8%
2025Q4Eper share2026-01-20-0.450.0%
2025Q4Rper share2026-01-20-0.610.0%
2025Q4Sper share2026-01-080.00-
2025Q3Eper share2025-10-03-0.57-
2025Q3Rper share2025-10-03-0.46-
2025Q3Sper share2025-10-030.00-

Estimate history

Annual
Metric2022202320242025TTMMRQ
EPS per share-0.639-0.28-2.812-0.996-4.6259-
Sales USD millions00000-
Shares million shares22222225-32
Quarterly
MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
EPS per share-0.632-0.226-0.21-0.217-0.141-0.453-0.675-1.712-1.786
Sales USD millions000000000
Shares million shares222225222525292932

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/2022
Total Revenue0.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.390.32+255.6%0.090.000.00
Gross Profit-0.39-0.32-0.09-0.00-0.00
Selling, General and Administrative Excl. Other152.0030.08-53.5%64.74+469.4%11.37+304.6%2.81
Research and Development118.7916.74-67.3%51.17+552.7%7.84+480.7%1.35
Other Operating Expense0.000.000.000.000.00
Operating Income-152.39-30.40-64.83-11.38-2.81
Interest Expense0.000.000.00-100.0%4.83+124.7%2.15
Unusual Expense1.21-1.16-222.1%0.95-8.82-193.2%9.46
Net Income Before Taxes-141.19-25.20-63.10-6.27-14.35
Income Taxes0.000.000.000.000.00
Consolidated Net Income-141.19-25.20-63.10-6.28-14.35
Net Income From Continuing Operations-141.19-25.20-63.10-6.28-14.35
Net Income-141.19-25.20-63.10-6.28-14.35
EPS (Recurring) per share-4.24-1.03-2.78-0.55-0.34
EPS (Basic, Before Extraordinaries) per share-4.63-1.00-2.81-0.28-0.64
EPS (Diluted) per share-4.63-1.00-2.81-0.28-0.64
EBITDA-152.00-30.08-64.74-11.37-2.81
Non-Operating Income (Expense)12.404.04+50.7%2.68+143.6%1.10+1471.4%0.07
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense12.953.31+35.7%2.44+960.9%0.230.00
Shares Outstanding million shares32.2725.30+12.7%22.440.0%22.440.0%22.44
Market Capitalization1,374.131,374.13+152.6%543.93--

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.12+50.0%0.10+25.0%0.080.0%0.09+12.5%0.08+700.0%0.080.080.08
Gross Profit-0.12-0.10-0.08-0.09-0.08-0.08-0.08-0.08
Selling, General and Administrative Excl. Other62.37+1106.4%53.82+1025.9%22.02+246.8%13.79+152.6%5.17-67.8%4.78-82.0%6.35-61.8%5.46
Research and Development51.52+2028.9%44.15+1724.4%14.64+328.1%8.48+2131.6%2.42-77.3%2.42-90.1%3.42-78.2%0.38
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-62.50-53.91-22.10-13.87-5.25-4.86-6.43-5.54
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.340.66+247.4%-0.200.40+110.5%-0.980.19-87.8%-0.77-466.7%0.19
Net Income Before Taxes-59.07-51.60-19.05-11.47-3.56-4.87-5.31-5.07
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-59.07-51.60-19.05-11.47-3.56-4.87-5.31-5.07
Net Income From Continuing Operations-59.07-51.60-19.05-11.47-3.56-4.87-5.31-5.07
Net Income-59.07-51.60-19.05-11.47-3.56-4.87-5.31-5.07
EPS (Recurring) per share-1.78-1.70-0.68-0.44-0.17-0.21-0.23-0.22
EPS (Basic, Before Extraordinaries) per share-1.79-1.71-0.67-0.45-0.14-0.22-0.21-0.23
EPS (Diluted) per share-1.79-1.71-0.67-0.45-0.14-0.22-0.21-0.23
EBITDA-62.37-53.82-22.02-13.79-5.17-4.78-6.35-5.46
Non-Operating Income (Expense)3.77+431.0%2.97+1550.0%2.85+714.3%2.80+324.2%0.71-20.2%0.18-60.0%0.35-48.5%0.66
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.63+312.5%4.90+1384.8%2.57+301.6%1.85+13.5%0.88+87.2%0.33+22.2%0.64+814.3%1.63
Shares Outstanding million shares32.27+27.5%28.68+27.8%28.67+13.3%25.30+12.7%25.30+12.7%22.440.0%25.30+12.7%22.44
Market Capitalization1,374.13+287.8%930.70+172.1%707.12563.16354.38342.03--

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/2022
Cash & Short Term Investments295.21+954.3%28.00-35.3%43.29+102.3%21.40
Short Term Receivables0.000.000.000.00
Inventories0.000.000.000.00
Other Current Assets13.22+1402.3%0.88-62.4%2.34+2500.0%0.09
Total Current Assets308.43+968.0%28.88-36.7%45.63+112.3%21.49
Net Property, Plant & Equipment3.73-10.3%4.16+20700.0%0.020.00
Total Investments and Advances0.77+54.0%0.500.000.00
Long-Term Note Receivable--0.00-
Intangible Assets0.000.000.000.00
Other Assets0.000.00-100.0%0.010.00
Total Assets312.93+833.3%33.53-26.6%45.66+112.5%21.49
Short Term Debt Incl. Current Port. of LT Debt0.73+49.0%0.490.000.00
Accounts Payable2.13-8.2%2.32+66.9%1.39+768.8%0.16
Other Current Liabilities4.58-13.6%5.30+334.4%1.22+293.5%0.31
Total Current Liabilities7.44-8.3%8.11+210.7%2.61+455.3%0.47
Long Term Debt2.84-11.8%3.220.00-100.0%24.15
Provision for Risks Charges0.000.000.000.00
Other Liabilities1.34-46.4%2.50+60.3%1.56-91.6%18.49
Total Liabilities11.62-16.0%13.83+232.5%4.16-90.4%43.11
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.00-100.0%114.26+50.4%75.97+956.6%7.19
Common Equity301.31-94.55-34.47-28.81
Total Shareholders Equity301.31+1429.5%19.70-52.5%41.49-21.62
Accumulated Minority Interest0.000.000.000.00
Total Equity301.31+1429.5%19.70-52.5%41.49-21.62
Total Liabilities & Stockholders Equity312.93+833.3%33.53-26.6%45.66+112.5%21.49
Book Value Per Share per share11.91-4.21-1.54-1.28
Tangible Book Value Per Share per share11.91-4.21-1.54-1.28
Full-Time Employees people27+68.8%16--
Price to Book Ratio ratio3.281.75--
Return on Assets %-14.55-159.37-18.69-
Return on Equity %-15.70-206.22-63.14-
Return on Invested Capital %-8.29-275.30-15.12-567.11
Quick Ratio ratio41.443.5617.5145.82
Current Ratio ratio41.443.5617.5145.82

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/2022
Net Income-141.19-25.20-63.10-6.28-14.35
Depreciation0.390.32+255.6%0.090.000.00
Other Funds (Non Cash)14.553.33-49.9%6.65-4.51-139.1%11.53
Funds from Operations-126.26-21.56-56.37-10.78-2.81
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-17.06-13.65-512.4%3.31-1.31-1555.6%0.09
Cash from Operating Activities-143.31-35.21-53.05-12.09-2.73
Capital Expenditures-0.51-0.05-0.77-0.030.00
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments-144.13-39.84-266.0%24.00-27.98-23416.7%0.12
Purchase of Investments-166.14-44.84-29.75-33.980.00
Sale Or Maturity of Investments22.015.00-90.7%53.75+795.8%6.00+4900.0%0.12
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-144.64-39.89-271.7%23.23-28.01-23441.7%0.12
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock233.56302.56+689.8%38.31+16.0%33.04+5229.0%0.62
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock233.56302.56+689.8%38.31+16.0%33.04+5229.0%0.62
Proceedsfrom Stock Options233.44302.31+689.5%38.29+15.9%33.04+5229.0%0.62
Issuance or Reduction of Debt, Net0.000.000.00-100.0%0.64-97.1%22.34
Change in Long Term Debt0.000.000.00-100.0%0.64-97.1%22.34
Issuance of Long Term Debt0.000.000.00-100.0%0.64-97.1%22.34
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities233.56302.56+689.8%38.31+13.7%33.68+46.7%22.96
Net Change in Cash-54.39227.47+2576.1%8.50-6.42-131.5%20.36
Free Cash Flow-143.82-35.26-53.82-12.12-2.73
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q22025Q12024Q412/31/2024
Cash & Short Term Investments403.76+28.4%327.79365.64295.21+954.3%314.48--28.00
Short Term Receivables0.000.000.000.000.00--0.00
Inventories0.000.000.000.000.00--0.00
Other Current Assets43.36+2158.3%27.5123.4413.22+1402.3%1.92--0.88
Total Current Assets447.12+41.3%355.30389.07308.43+968.0%316.40--28.88
Net Property, Plant & Equipment5.46+42.6%5.613.633.73-10.3%3.83--4.16
Total Investments and Advances0.79+54.9%0.780.780.77+54.0%0.51--0.50
Intangible Assets0.000.000.000.000.00--0.00
Other Assets0.000.000.000.000.00--0.00
Total Assets453.37+41.3%361.69393.48312.93+833.3%320.75--33.53
Short Term Debt Incl. Current Port. of LT Debt0.96+31.5%0.840.730.73+49.0%0.73--0.49
Accounts Payable6.88+165.6%3.497.122.13-8.2%2.59--2.32
Other Current Liabilities22.41+573.0%19.233.064.58-13.6%3.33--5.30
Total Current Liabilities30.25+354.9%23.5610.917.44-8.3%6.65--8.11
Long Term Debt4.20+42.9%4.372.742.84-11.8%2.94--3.22
Provision for Risks Charges0.000.000.000.000.00--0.00
Other Liabilities1.28+36.2%1.411.141.34-46.4%0.94--2.50
Total Liabilities35.73+239.3%29.3414.7911.62-16.0%10.53--13.83
Non-Equity Reserves0.000.000.000.000.00--0.00
Preferred Stock - Carrying Value0.000.000.000.00-100.0%0.00--114.26
Common Equity417.64+34.6%332.35378.69301.31310.22---94.55
Total Shareholders Equity417.64+34.6%332.35378.69301.31+1429.5%310.22--19.70
Accumulated Minority Interest0.000.000.000.000.00--0.00
Total Equity417.64+34.6%332.35378.69301.31+1429.5%310.22--19.70
Total Liabilities & Stockholders Equity453.37+41.3%361.69393.48312.93+833.3%320.75--33.53
Book Value Per Share per share12.94+5.5%11.5913.2111.9112.26---4.21
Tangible Book Value Per Share per share12.94+5.5%11.5913.2111.9112.26---4.21
Full-Time Employees people---27+68.8%---16
Price to Book Ratio ratio3.282.462.071.82----
Return on Assets %-36.48---14.55----
Return on Equity %-38.80---15.70----
Return on Invested Capital %-14.00-15.33-5.00-3.77-1.14---22.12
Quick Ratio ratio14.7815.0835.6841.4447.60--3.56
Current Ratio ratio14.7815.0835.6841.4447.60--3.56

Cash flow, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Net Income-59.07-51.60-19.05-11.47-3.56-4.87-5.31-5.07
Depreciation0.12+50.0%0.10+25.0%0.080.0%0.09+12.5%0.08+700.0%0.080.080.08
Other Funds (Non Cash)3.72+1760.0%5.59+1142.2%2.432.81+28.9%0.20-90.7%0.45-78.6%-0.13-156.5%2.18
Funds from Operations-55.23-45.92-16.54-8.57-3.28-4.35-5.36-2.81
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-9.078.29-6.75-9.53-0.10-1.25-112.7%-2.77-143.6%-2.85
Cash from Operating Activities-64.29-37.63-23.29-18.10-3.37-5.60-8.13-5.67
Capital Expenditures-0.07-0.36-3700.0%-0.03-0.040.000.01-0.02-0.24
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-144.580.450.00-100.0%0.00-100.0%-44.84-252.9%0.00-100.0%5.0013.78
Purchase of Investments-156.40-9.750.000.00-44.840.000.000.00
Sale Or Maturity of Investments11.8110.200.00-100.0%0.00-100.0%0.00-100.0%0.00-100.0%5.0013.78
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-144.650.09+800.0%-0.03-100.6%-0.04-100.3%-44.84-255.3%0.01-99.9%4.9813.54
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock140.92-53.6%-0.0293.83-1.17303.73+1518550.0%0.000.00-100.0%0.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock140.92-53.6%-0.0293.83-1.17303.73+1518550.0%0.000.00-100.0%0.00
Proceedsfrom Stock Options140.87-53.6%-0.0793.80-1.17303.490.000.00-100.0%0.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities140.92-53.6%-0.0293.83-1.17303.73+1518550.0%0.000.00-100.0%0.00
Net Change in Cash-68.03-126.6%-37.5670.51-19.31-345.4%255.52+3624.8%-5.59-3.15-218.9%7.87
Free Cash Flow-64.36-37.99-23.32-18.14-3.37-5.59-8.15-5.90

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3025.83%6.2M24.0M367.61K
2026-10-1523.26%5.6M23.9M371.55K
2026-09-3025.13%6.0M23.9M334.72K
2026-09-1523.48%5.6M23.9M343.04K
2026-08-3122.07%5.3M23.9M326.59K
2026-08-1421.56%5.2M23.9M315.33K
2026-07-3122.87%4.7M20.8M266.85K
2026-07-1520.52%4.3M20.8M244.82K
2026-06-3021.92%4.6M20.8M263.70K
2026-06-1520.73%4.3M20.8M231.96K
2026-05-2919.34%4.0M20.8M239.97K
2026-05-1519.36%4.0M20.8M248.35K
2026-04-3017.83%3.8M21.3M258.42K
2026-04-1514.60%3.1M21.3M245.29K
2026-03-3112.30%2.6M21.3M229.51K
2026-03-1314.43%2.7M18.8M307.24K
2026-02-2713.91%2.6M18.8M309.39K
2026-02-1311.70%2.2M18.8M295.74K
2026-01-309.60%1.8M18.8M281.58K
2026-01-159.53%1.8M18.8M262.56K

Option chain

Expiry 2026-11-20 · underlying 42.46, quoted 12 Nov 15:59 ET · ATM 40.00

Option quotes 11 Nov 09:30 ET. A date on a row is older than the last session (12 Nov). 20 rows.

Implied move 14.72% into expiry (call 3.750 + put 2.500 = 6.250 on 42.46)

Put/call open interest 0.24 (55 puts / 231 calls) · Put/call volume — no calls

IV change is points against the prior close.

TypeStrikeMoneyBidAskLastChgIVOpen intVolumeLast sizeDeltaThetaVega
call 1 Jan22.50ITM18.0022.500.000.00517.8% -196.30000.871-0.5980.013
put 1 JanOTM0.005.000.000.00714.0% 0.0000-0.129-0.5950.013
call 1 Jan25.00ITM15.3020.000.000.00453.1% -177.50000.850-0.5850.015
put 5 NovOTM0.005.000.600.00630.6% 0.0100-0.150-0.5830.015
call 1 Jan30.00ITM10.3015.000.000.00341.0% -148.00000.801-0.5440.017
put 1 JanOTM0.005.000.000.00489.0% 0.0000-0.199-0.5410.017
call 1 Jan35.00ITM5.3010.000.000.00243.2% -125.10000.735-0.4810.020
put 30 SepOTM0.005.002.070.00368.3% 0.0200-0.265-0.4770.020
call 5 Nov40.00ATM1.506.001.750.00185.4% -62.6227000.643-0.3710.023
put 2 NovATM0.005.003.000.00257.7% +13.25200-0.364-0.3620.023
call 11 Nov45.00OTM0.005.002.000.00162.1% 0.04000.451-0.2570.025
put 1 JanITM1.005.500.000.00162.1% 0.0000-0.549-0.2520.025
call 1 Jan50.00OTM0.005.000.000.00224.4% 0.00000.371-0.3380.023
put 1 JanITM5.009.700.000.00188.7% -35.4000-0.630-0.3310.024
call 1 Jan55.00OTM0.005.000.000.00273.3% 0.00000.328-0.3930.022
put 1 JanITM10.0014.600.000.00227.3% -45.8000-0.672-0.3870.022
call 1 Jan60.00OTM0.005.000.000.00314.1% 0.00000.302-0.4360.022
put 1 JanITM15.0019.700.000.00276.3% -37.6000-0.698-0.4290.022
call 1 Jan65.00OTM0.005.000.000.00349.2% 0.00000.283-0.4700.021
put 1 JanITM20.0024.600.000.00299.9% -49.2000-0.717-0.4620.021

Latest SEC filings

30 of 143
AllAll annual, quarterly, and current reportsInsider equity awards, transactions, and ownership (Section 16 Reports)Beneficial ownership reportsExempt offeringsRegistration statements and prospectusesFiling review correspondenceSEC orders and noticesProxy materialsTender offers and going private transactionsTrust indenture filings

10-Q filed 2026-11-05, period ended 2026-09-30. 10-K filed 2026-03-26, period ended 2025-12-31. LBRX on EDGAR

page 1 of 5Next →
FiledFormDescriptionPeriodDocument
2026-11-0510-QAll annual, quarterly, and current reports2026-09-300001193125-26-449994 index
2026-11-058-KAll annual, quarterly, and current reports2026-11-050001193125-26-449887 index
2026-10-134Insider equity awards, transactions, and ownership (Section 16 Reports)2026-10-09 · transaction0002150267-26-000005 index
2026-10-134Insider equity awards, transactions, and ownership (Section 16 Reports)2026-10-09 · transaction0001746372-26-000007 index
2026-10-13SCHEDULE 13G/ABeneficial ownership reportsno report period0000019617-26-000360 index
2026-10-05EFFECTSEC orders and noticesno report period9999999995-26-003150 index
2026-10-01POS AMRegistration statements and prospectusesno report period0001193125-26-410664 index
2026-10-01S-3ASRRegistration statements and prospectusesno report period0001193125-26-410651 index
2026-09-243Insider equity awards, transactions, and ownership (Section 16 Reports)2026-09-140002150267-26-000003 index
2026-09-15424B3Registration statements and prospectusesno report period0001193125-26-391384 index
2026-09-158-KAll annual, quarterly, and current reports2026-09-150001193125-26-391358 index
2026-09-143Insider equity awards, transactions, and ownership (Section 16 Reports)2026-09-020001746372-26-000005 index
2026-09-03424B3Registration statements and prospectusesno report period0001193125-26-381100 index
2026-09-038-KAll annual, quarterly, and current reports2026-09-030001193125-26-381076 index
2026-08-14SCHEDULE 13G/ABeneficial ownership reportsno report period0001193125-26-352336 index
2026-08-11424B3Registration statements and prospectusesno report period0001193125-26-343542 index
2026-08-1110-QAll annual, quarterly, and current reports2026-06-300001193125-26-343490 index
2026-08-118-KAll annual, quarterly, and current reports2026-08-110001193125-26-343479 index
2026-08-034Insider equity awards, transactions, and ownership (Section 16 Reports)2026-07-30 · transaction0001193125-26-331058 index
2026-07-29SCHEDULE 13G/ABeneficial ownership reportsno report period0002012383-26-002809 index
2026-07-29424B3Registration statements and prospectusesno report period0001193125-26-322276 index
2026-07-298-KAll annual, quarterly, and current reports2026-07-280001193125-26-322208 index
2026-07-22424B3Registration statements and prospectusesno report period0001193125-26-311394 index
2026-07-228-KAll annual, quarterly, and current reports2026-07-220001193125-26-311357 index
2026-07-16SCHEDULE 13GBeneficial ownership reportsno report period0000019617-26-000264 index
2026-06-10424B3Registration statements and prospectusesno report period0001193125-26-266020 index
2026-06-108-KAll annual, quarterly, and current reports2026-06-080001193125-26-265867 index
2026-06-09144no categoryno report period0001972481-26-000189 index
2026-06-09424B3Registration statements and prospectusesno report period0001193125-26-263737 index
2026-06-098-KAll annual, quarterly, and current reports2026-06-030001193125-26-263724 index

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Deep Track Capital, LP11.69%
BlackRock, Inc.9.53%
RA CAPITAL MANAGEMENT, L.P.7.70%
Nantahala Capital Management, LLC7.34%
Trails Edge Capital Partners, LP5.31%
Commodore Capital LP5.23%
TCG Crossover Management, LLC5.05%
Caligan Partners LP5.01%
Spruce Street Capital LP4.80%
JPMORGAN CHASE & CO4.48%

Funds

Fund% owned
JPMorgan Small Cap Growth Fund2.42%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.34%
iShares Russell 2000 ETF2.03%
BlackRock Health Sciences Opportunities Portfolio1.76%
VANGUARD EXTENDED MARKET INDEX FUND0.97%
Fidelity Small Cap Index Fund0.85%
JPMorgan Small Cap Blend Fund0.77%
BlackRock Health Sciences Term Trust0.73%
PGIM Jennison Health Sciences Fund0.72%
Fidelity Growth Company Fund0.62%

OakChart. LBRX. Cached 15 minutes. Terms